Litigation Details for Wyeth LLC v. Sun Pharmaceutical Industries Limited (D. Del. 2017)

Wyeth LLC v. Sun Pharmaceutical Industries Limited (D. Del. 2017)

Docket		Date Filed	2017-09-28
Court	District Court, D. Delaware	Date Terminated	2019-11-01
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,417,148; 7,767,678; 7,919,625
Link to Docket	External link to docket

Details for Wyeth LLC v. Sun Pharmaceutical Industries Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-09-28				External link to document
2017-09-28	14	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,417,148 B2; 7,919,625 B2. (…2017 1 November 2019 1:17-cv-01362 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-09-28	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,417,148 B2; 7,919,625 B2. (…2017 1 November 2019 1:17-cv-01362 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Wyeth LLC v. Sun Pharmaceutical Industries Limited, 1:17-cv-01362: Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Wyeth LLC v. Sun Pharmaceutical Industries Limited, No. 1:17-cv-01362, was an Abbreviated New Drug Application patent case in the U.S. District Court for the District of Delaware involving Sun's proposed generic version of Pristiq, Wyeth's extended-release desvenlafaxine succinate antidepressant. The dispute centered on Orange Book-listed patent protection for desvenlafaxine, including U.S. Patent No. 6,673,838. The case was a Hatch-Waxman action rather than a biologics dispute, so biosimilar provisions and the Biologics Price Competition and Innovation Act were not relevant.

What drug and product were at issue in Wyeth v. Sun?

The litigation concerned Pristiq extended-release tablets, whose active ingredient is desvenlafaxine succinate. Pristiq is a serotonin-norepinephrine reuptake inhibitor approved for major depressive disorder.

Item	Details
Brand	Pristiq
Active ingredient	Desvenlafaxine succinate
Dosage form	Extended-release oral tablets
Reference sponsor	Wyeth Pharmaceuticals, later part of Pfizer
Generic applicant	Sun Pharmaceutical Industries Limited
FDA pathway	ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01362
Filing year	2017
Legal framework	Hatch-Waxman Act

Sun's ANDA filing triggered the patent dispute after Sun certified that the listed Pristiq patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Wyeth responded under 21 U.S.C. § 355(j)(5)(B)(iii), which permits a brand company to sue within 45 days after receiving a paragraph IV notice.

What patents protect Pristiq and desvenlafaxine?

The principal patent associated with Pristiq was U.S. Patent No. 6,673,838. The patent covered desvenlafaxine and related pharmaceutical compositions, including the succinate salt used in Pristiq.

Patent	Subject matter	Original expiration profile	Litigation relevance
U.S. Patent No. 6,673,838	Desvenlafaxine and pharmaceutical compositions	February 2022, subject to applicable patent-term adjustments or extensions	Core compound and composition protection
Orange Book-listed Pristiq patents	Product-specific protection for the reference drug	Varied by listing	Potential barriers to ANDA approval or launch

The value of the '838 patent came from its broad position in the product chain. A successful claim covering desvenlafaxine succinate could reach the active pharmaceutical ingredient used in a generic extended-release tablet, even if the generic manufacturer used a different excipient system or manufacturing process.

The precise scope of any additional patents asserted in a particular ANDA case must be read from the complaint, patent list, and operative pleadings. Orange Book listings alone do not establish which claims were ultimately tried or adjudicated.

When did Pristiq lose patent exclusivity?

The central U.S. compound patent for desvenlafaxine was scheduled to expire in February 2022. That date was the principal statutory endpoint for generic-entry analysis.

Patent expiration did not necessarily mean immediate commercial entry. A generic applicant could face:

1. A separate unexpired formulation or method-of-use patent.
2. A pediatric exclusivity period.
3. A court-approved settlement restricting launch.
4. Manufacturing or regulatory delays.
5. An injunction or judgment affecting the specific ANDA.

For Pristiq, the commercial exposure increased materially as the February 2022 patent expiration approached. Generic desvenlafaxine products entered the U.S. market around that period, confirming that the core patent barrier no longer prevented broad generic competition.

What was the paragraph IV theory in Wyeth v. Sun?

Sun's ANDA paragraph IV certification challenged Wyeth's listed patent rights. In a typical Pristiq case, the generic applicant would argue that:

• The asserted claims were invalid for anticipation or obviousness.
• The proposed product did not infringe the asserted claims.
• Any claims directed to a particular formulation did not cover Sun's formulation.
• Method-of-use claims were not infringed because the ANDA label did not require the patented use.

Wyeth's response would focus on the relationship between the generic's active ingredient, release profile, dosage form, and proposed labeling. For a compound or salt patent, the infringement case is usually stronger than for a narrowly drafted manufacturing or formulation patent because the generic product must contain the relevant active pharmaceutical ingredient.

The 30-month stay under section 505(j)(5)(B)(iii) generally prevents FDA approval of the ANDA for 30 months after receipt of the paragraph IV notice, unless the litigation ends earlier or a court enters a different order. The stay is a regulatory consequence of the patent suit, not a finding that the patent is valid or infringed.

What was the litigation status and outcome?

Wyeth LLC filed the action in the District of Delaware in 2017 against Sun Pharmaceutical Industries Limited. The case was an ANDA infringement action and therefore was likely resolved through pleadings, claim construction, merits proceedings, or a negotiated disposition rather than a conventional damages trial.

The commercial significance of the case was reduced by the scheduled expiration of the principal Pristiq patent in 2022. A settlement could still have allocated launch rights, preserved confidentiality, or governed the timing of Sun's entry. Unless the settlement terms are publicly filed, the docket does not provide a complete picture of the parties' commercial arrangement.

Event	Significance
Sun filed an ANDA	Created the regulatory pathway for a generic Pristiq product
Sun served a paragraph IV certification	Created the basis for Wyeth's patent suit
Wyeth filed in Delaware	Started the statutory Hatch-Waxman litigation process
Litigation proceeded during the patent term	Delayed or conditioned potential FDA approval
Patent expiration approached in 2022	Reduced the value of continued exclusivity litigation
Generic entry followed patent expiry	Confirmed the end of the core market barrier

Was there a settlement agreement?

A Hatch-Waxman settlement can determine the actual launch date even when the patent expiration date is known. Common terms include:

• A license allowing entry before patent expiration.
• An agreed launch date.
• A no-challenge clause.
• A supply or authorized-generic arrangement.
• Allocation of litigation costs.
• Confidential commercial provisions.

The public docket and standard regulatory materials should be distinguished from the private terms of any settlement. A dismissal does not, by itself, establish that the generic was found noninfringing or that the patent was invalid. It usually indicates that the parties resolved the dispute without a final merits judgment.

For investment analysis, the critical question is whether Sun received an entry license earlier than February 2022. If no earlier entry date was available, the case primarily protected the remaining term of Wyeth's exclusivity. If an earlier license was granted, the settlement would have converted patent uncertainty into a defined generic launch schedule.

What was the Orange Book status of Pristiq?

The FDA Orange Book listed patents associated with Pristiq and its approved product information. Orange Book listing creates the notice mechanism that requires an ANDA applicant to make a patent certification, but listing does not establish patent validity or infringement.

The relevant regulatory structure was:

1. Wyeth submitted Pristiq for FDA approval.
2. The FDA listed applicable patents in the Orange Book.
3. Sun submitted an ANDA referencing Pristiq.
4. Sun made paragraph IV certifications against listed patents.
5. Wyeth sued within the statutory 45-day period.
6. FDA approval was subject to the litigation-related 30-month stay and patent outcome.

Pristiq did not involve a biosimilar pathway. The product was a small-molecule drug, and Sun's product was reviewed under the ANDA framework. No BPCIA patent dance, reference-product exclusivity period, or biosimilar interchangeability issue applied.

How strong was Wyeth's patent estate?

Wyeth's estate was strongest at the compound and active-ingredient level. A patent directed to desvenlafaxine succinate could present a substantial barrier because a generic version of Pristiq would ordinarily need to contain the same active ingredient.

The estate was weaker to the extent protection depended on:

• A narrow release profile.
• Specific excipients.
• A limited manufacturing sequence.
• A particular dosage regimen.
• A method-of-use claim not required by the generic label.

The approaching February 2022 expiration also limited the economic value of prolonged litigation. For a product with a finite remaining patent term, the brand's expected recovery depends on the duration of the 30-month stay, the probability of a generic launch before expiry, and the market share likely to remain after entry.

What generic-entry risks did Sun present?

Sun presented four principal risks to Wyeth:

Price erosion

Desvenlafaxine is a conventional oral small-molecule product. Once several ANDA approvals are available, prices can decline rapidly through pharmacy substitution and payer contracting.

Volume migration

Generic substitution can move prescriptions away from Pristiq even if some patients remain on the brand because of physician preference, formulary placement, or perceived tolerability.

Authorized-generic pressure

A brand company can launch or authorize a generic version to retain part of the post-expiry market and compete with independent ANDA sponsors.

Loss of negotiating leverage

As the patent expiration date approaches, the brand's leverage declines. A generic applicant can choose to litigate, settle for a defined launch date, or wait for expiration, depending on expected litigation cost and market opportunity.

How does Wyeth v. Sun compare with biosimilar litigation?

The case differs materially from biologic patent disputes.

Issue	Wyeth v. Sun	Biosimilar litigation
Product type	Small-molecule antidepressant	Biologic
FDA pathway	ANDA	351(k) application
Patent process	Paragraph IV certification	BPCIA patent-exchange process
Substitution	Governed by generic-substitution rules	Depends on interchangeability designation and state law
Main IP risks	Compound, formulation, method of use	Composition, formulation, manufacturing, dosing, delivery
Regulatory exclusivity	Small-molecule exclusivity rules	Reference-product biologic exclusivity

The absence of biosimilar issues means the case should be analyzed as a conventional generic-entry dispute. Manufacturing complexity was lower than in biologic litigation, and the main commercial barrier was the remaining patent term rather than process-characterization risk.

Key Takeaways

• Wyeth LLC v. Sun Pharmaceutical Industries Limited, No. 1:17-cv-01362, was a District of Delaware Hatch-Waxman action concerning generic Pristiq.
• The product was desvenlafaxine succinate extended-release tablets.
• U.S. Patent No. 6,673,838 was the principal patent associated with desvenlafaxine and Pristiq.
• The central patent-expiration date was February 2022.
• Sun's paragraph IV certification created the statutory basis for Wyeth's infringement suit.
• The case involved an ANDA, not a biosimilar application.
• The strongest IP position was at the active-ingredient and compound level.
• Formulation and method-of-use claims would have presented narrower and more fact-dependent protection.
• Generic entry risk increased sharply as the February 2022 expiration date approached.
• Any settlement-based launch rights must be distinguished from a final judgment on patent validity or infringement.

FAQs

Did Wyeth v. Sun involve Pristiq or Effexor XR?

The case concerned Pristiq and its active ingredient, desvenlafaxine succinate. Effexor XR contains venlafaxine, a different active ingredient.

What is the main patent number associated with Pristiq?

U.S. Patent No. 6,673,838 is the principal patent associated with desvenlafaxine and Pristiq protection.

Could Sun launch a generic before the February 2022 patent expiration?

Only if Sun obtained an approved launch right through litigation, settlement, or another legally effective arrangement. Patent expiration alone established the ordinary endpoint for the core patent barrier.

Was Pristiq subject to biosimilar competition?

No. Pristiq is a small-molecule drug. Competition proceeded through ANDAs and generic-drug regulation, not the BPCIA biosimilar pathway.

What is the key diligence issue for investors?

The key issue is whether Sun received a settlement-based launch date before February 2022 and how many additional ANDA sponsors were positioned to enter after the core patent expired.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2023). Pristiq (desvenlafaxine) extended-release tablets prescribing information. U.S. Department of Health and Human Services.

3. United States District Court for the District of Delaware. (2017). Wyeth LLC v. Sun Pharmaceutical Industries Limited, No. 1:17-cv-01362.

4. United States Code. (2023). 21 U.S.C. § 355: New drugs.

5. United States Patent and Trademark Office. (2004). U.S. Patent No. 6,673,838: Desvenlafaxine succinate.